Opinion|Videos|April 29, 2026

Final Thoughts on Management of Treatment Resistant Depression

Learn how clinicians safely add esketamine nasal spray: REMS setup, two-hour monitoring, vitals checks, referrals, and patient-centered collaboration.

In this episode, panelists closed the discussion on an optimistic note, emphasizing that TRD treatment has entered a transformative era with better tools than ever before. The key message was that clinicians must become more aggressive — not just in treatment selection, but in speed of intervention, flexibility of approach, and willingness to combine modalities. Treatments are not mutually exclusive and need not follow a rigid stepwise ladder; they can and should be mixed based on individual patient needs. Accurate diagnosis, thorough identification of contributing factors, and genuine attention to patient preferences were highlighted as foundational to success. Panelists noted that individualizing care not only improves outcomes but strengthens the therapeutic relationship, keeping patients engaged in treatment. With promising new options already on the horizon, the overall outlook for TRD was described as highly encouraging — a moment of real opportunity for clinicians willing to embrace a more proactive, patient-centered approach.

Thank you for watching this Psychiatric Times Peer Exchange series on treatment resistant depression. Please subscribe to our enewsletter for information on upcoming video series.